Third Rock-backed au­toim­mune biotech turns off the lights

A Third Rock Ven­tures biotech cre­at­ed to make new med­i­cines for au­toim­mune and in­flam­ma­to­ry dis­eases has shut­tered, End­points News has learned.

Rheos Med­i­cines changed its reg­is­tered of­fice ad­dress and reg­is­tered agent last month to that of a Foxbor­ough, MA ac­count­ing firm that spe­cial­izes in bank­rupt­cies, per Jan­u­ary doc­u­ments. A Third Rock spokesper­son con­firmed to End­points that Rheos wound down “late last year.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.